TABLE 1.
Demographics of study cohort describing the donor–recipient clinical details, induction agents, antibody removal techniques, and early clinical outcomes
| Total | O | B | |
|---|---|---|---|
| Number | 65 | 53 | 12 |
| Recipient sex (female, n [%]) | 26 (40%) | 20 (37.8%) | 6 (50%) |
| Recipient age mean (SD) | 47.8 (13.1) | 48.0 (13.1) | 47.2 (13.7) |
| Recipient ethnicity (Caucasian) n (%) | 61 (93.8%) | 51 (96.3%) | 10 (83.3%) |
| Recipient CMV positive n (%) | 23 (37.8%) | 17 (33.3%) | 6 (60%) |
| Calculated reaction frequency = 0% | 62 (95.3%) | 50 (94.3%) | 12 (100%) |
| HLA ABDR mismatch median (Q1–Q3) | 3 (2–4) | 3 (2–4) | 4(3–5) |
| Pre‐emptive n (%) | 29 (44.6%) | 23 (43.4%) | 6 (50%) |
| Retransplants n (%) | 9 | 9 | 0 |
| Donor sex (female, n [%]) | 35 (53.8%) | 26 (49.1%) | 9 (75%) |
| Donor age mean (SD) | 48.7 (11.3) | 48.3 (11.5) | 50.7 (10.7) |
| Donor ethnicity (Caucasian) n (%) | 61 (93.8%) | 51 (96.3%) | 10 (83.3%) |
| Donor CMV positive n (%) | 31 (47.7%) | 24 (45.3%) | 7 (58.3%) |
| Relationship | |||
| Spouse n (%) | 26 (40%) | 18 (34.0%) | 8 (66.7%) |
| Extracorporeal antibody removal (EART) | |||
| Therapeutic plasma exchange n (%) | 23 (35.4%) | 23 (43.4%) | 1 (8.3%) |
| Immunoadsorption n (%) | 37 (56.9%) | 29 (54.7%) | 8 (66.7%) |
| No antibody removal n (%) | 4 (6.2%) | 1 (1.9%) | 3 (25%) |
| Rituximab n (%) | 57 (87.7%) | 47 (88.7%) | 10 (83.3%) |
| No lymphocyte depletion n (%) | 5 (7.7%) | 3 (5.7%) | 2 (16.7%) |
| Alemtuzumab n (%) | 3 (4.6%) | 3 (5.7%) | 0 (0%) |
| Basiliximab n (%) | 33 (50.8%) | 24 (45.3%) | 9 (75%) |
| Combined | |||
| Rituximab and basiliximab n (%) | 25 (38.5%) | 18 (34.0%) | 7 (58.3%) |
| Alemtuzumab and basiliximab n (%) | 3 (4.6%) | 3 (5.7%) | 0 (0%) |
| eGFR (MDRD, ml/min/BSA) | |||
| 3‐month mean (SD) | 49.6 (17.9) | 50.5 (18.6) | 46.0 (15.1) |
| 12‐month mean (SD) | 53 (18.3) | 55.4 (18.8) | 44.5 (13.7) |
| Graft failure n (%) | 5 (7.7%) | 5 (9.4%) | 0 (0%) |
| Biopsy‐proven rejection first month | 12 (18.5%) | 8 (15.1%) | 4 (33.3%) |
| Antibody‐mediated rejection n (%) | 3 (4.6%) | 2 (3.8%) | 1 (8.3%) |
| Cellular n (%) | 9 (13.8%) | 6 (11.3%) | 3 (25%) |
| Banff 1A n (% of rejections a ) | 5 (55.6%) | 4 (66.7%) | 1 (33.3%) |
| Banff 1B n (% of rejections a ) | 3 (33.3%) | 2 (33.3%) | 1 (33.3%) |
| Banff 2A n (% of rejections a ) | 1 (11.1%) | 0 | 1 (33.3%) |
Calculated Reaction Frequency is the UK equivalent of CPRA—degree of sensitization; eGFR (estimated Glomerular Filtration Rate using MDRD equation).
a
Percentage of cellular rejection.